CRISPR Therapeutics AG

Latest CRISPR Therapeutics AG News and Updates

  • CRISPR Therapeutics logo over DNA sequence
    Company & Industry Overviews

    Why CSRP Stock Is a Good Buy Despite Losses

    Genomic innovation takes time. However, CRISPR Therapeutics (CRSP) stock is still a smart bet. What can investors expect from the stock?
    By Rachel Curry
  • Woman reviewing data
    Company & Industry Overviews

    The Best Gene-Editing ETF for Your Portfolio in 2021

    Gene editing is a new horizon in the scientific community. What's the best gene-editing ETF for investors in 2021?
    By Rachel Curry
  • uploads///microbiology _
    Company & Industry Overviews

    Why CRISPR Therapeutics Stock Rose ~13.05% Yesterday

    On January 7, CRISPR Therapeutics stock rose ~13.05% to $34.22 from its previous close of $30.27 on January 4.

    By Daniel Collins
  • uploads///Sangamo
    Company & Industry Overviews

    A Financial Overview of Sangamo Therapeutics in December 2018

    In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million.

    By Daniel Collins
  • uploads///EDIT
    Company & Industry Overviews

    Editas Stock: Analysts’ Recommendations

    In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.”

    By Kenneth Smith
  • uploads///flasks _
    Company & Industry Overviews

    CRISPR Therapeutics: Analysts’ View in November

    On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8.

    By Daniel Collins
  • uploads///blood _
    Company & Industry Overviews

    How Is Vertex Pharmaceuticals Positioned in October?

    Vertex announced on October 10 that the FDA has lifted the clinical hold and accepted its Investigational New Drug Application for CTX001.

    By Kenneth Smith
  • uploads///Vertex
    Company & Industry Overviews

    Vertex Pharmaceuticals Strengthens in the Cystic Fibrosis Space

    Vertex Pharmaceuticals (VRTX) develops medicines for life-threatening diseases and is presently focused on developing drugs for cystic fibrosis and sickle-cell disease, partnering with CRISPR Therapeutics (CRSP) for the latter.

    By Daniel Collins
  • uploads///CRSP
    Company & Industry Overviews

    How CRISPR Therapeutics Is Positioned in September

    CRISPR Therapeutics (CRSP) reported net collaboration revenues of $1.1 million in the second quarter of 2018 compared to $3.6 million in the second quarter of 2017.

    By Daniel Collins
  • uploads///dna _
    Earnings Report

    How Analysts Rate Editas Medicine and Peers in August

    Editas Medicine (EDIT) is a research-stage genome editing company. Five of the total nine analysts covering the company in August have given the stock a “buy” rating.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Why Editas Medicine Fell 7.8% on Monday

    On June 11, Editas Medicine (EDIT) stock fell 7.8% over concerns that CRISPR CAS-9 Gene Therapy causes cancer.

    By Mike Benson
  • uploads///cells _
    Company & Industry Overviews

    CRISPR Stock Has Seen Soild Growth in the Last 12 Months

    CRISPR Therapeutics has risen 24% between May 11 and May 17.

    By Daniel Collins
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.